Biognosys Launches Spectronaut 19: Revolutionizing Proteomics at ASMS 2024
Biognosys, a leader in mass spectrometry-based proteomics solutions, is set to unveil Spectronaut 19 at the ASMS 2024 Annual Conference. This latest release boasts significant improvements in identifications, scalability, and support for novel workflows. Additionally, Biognosys will showcase groundbreaking technologies, including TrueDiscovery® P2 Plasma Enrichment and TrueTarget® high-throughput LiP-MS workflow. With the launch of Spectronaut 19, Biognosys is set to revolutionize the field of proteomics research.
Spectronaut® 19: Unleashing the Power of AI for Deep, Fast, and Scalable DIA Analysis
The latest version of Spectronaut offers a myriad of improvements, including enhanced quantification, increased depth of candidate discovery, and extended support for novel workflows. With the incorporation of advanced AI models, Spectronaut 19 sets a new standard for DIA analysis. Scientific experts have praised the software for its reliability and user-friendly interface, making it a preferred choice for analyzing complex datasets.
TrueDiscovery®: P2 Plasma Enrichment Technology for Deep Proteomics
Biognosys introduces the innovative P2 Plasma Enrichment method, providing unmatched performance and economics for deep plasma proteomics. This groundbreaking technology offers superior quantitation and throughput for biomarker discovery studies, setting a new benchmark in the field of proteomics research. The method will be available as a CRO service via TrueDiscovery® platform, offering researchers a powerful tool for unbiased and deep proteomics analysis.
TrueTarget®: High-throughput Workflow for Drug Target Deconvolution Screening
Addressing the critical challenge of drug target identification, Biognosys presents TrueTarget® platform powered by LiP-MS technology. This high-throughput workflow enables efficient screening of drug targets, with improved target identification and reduced measurement time. By offering a comprehensive solution for drug target deconvolution, Biognosys aims to accelerate drug discovery and development processes.
In conclusion, Biognosys’ launch of Spectronaut 19 and presentation of advanced research platforms at ASMS 2024 mark a significant milestone in the field of proteomics. With cutting-edge technologies and groundbreaking methodologies, Biognosys continues to drive innovation and excellence in proteomics research. Visit their website for more information on their latest developments and offerings.
